An attempt to vaccinate patients with autologous tumor-derived gp96 heat shock proteins (known to bind mutation-derived neo-TAAs) [21] led to tumor-specific T cell immune response in 50%–60% of metastatic colon carcinoma patients [22] with evidence of better survival in immune responders as compared to non-responders. The gene discussed is HSP90B1; the disease is neoplasm.